Pharmacokinetic, Pharmacodynamic and Safety Evaluation After Single Oral Administration of KRN1493

NCT00952094 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Healthy

Interventions

DRUG: KRN1493

Sponsor

Seoul National University Hospital

Collaborators

[object Object]
[object Object]